Figure 1.
Percent symptom reduction in 74 placebo and 92 antidepressant treatment arms from 85 clinical trials for 16 antidepressant approval programs plotted with time. The correlation between year of new drug approval and percent symptom reduction was significant in both the placebo (r=0.46, p<0.001) and the antidepressant group (r=0.37, p<0.001).